Catalyst

Slingshot members are tracking this event:

Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase 2b NASH study

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GLMD

100%

Additional Information

Additional Relevant Details
The ARREST Study primary endpoint, previously demonstrated in a Phase IIa study, is reduction in liver fat content measured by magnetic resonance spectroscopy (MRS).  The secondary histological endpoints include improvement of fibrosis, two-point improvement in NAS (NAFLD Activity Score) and resolution of NASH. The ARREST Study will also evaluate surrogate metabolic endpoints.Patients enrolled in the ARREST Study have advanced NASH with more than 60% having fibrosis in stages 2 (19%) and 3 (42%) and a mean NAS score of 5.
http://galmedpharma....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 09, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nash Study, Arrest, Phase 2b, Nash, Non-alcoholic Steatohepatitis